We recently conducted a retrospective analysis of our institutional cohort of high‐grade serous ovarian cancer patients subjected to tumor mutational profiling using the Memorial Sloan Kettering ‐ Integrated Mutation Profiling of Actionable Cancer Targets (MSK‐IMPACT) platform to identify rare cases that lack TP53 genetic alterations [6]. This evidence concerns the gene TP53 and cancer.